Upadacitinib in Concurrent Severe Pyoderma Gangrenosum and Crohn's Disease: Case Report and Literature Review

Chiara Maria Palmisano, Domenico Novielli, Lucia Pacello, Silvia Cormio, Valeria Borraccino, Francesco Squeo, Anna Maria Spadone, Teresa Sanità, Alfredo Di Leo and Mariabeatrice Rita Daniela Principi

Department of Interdisciplinary Medicine, University of Bari "Aldo Moro", Italy
Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Italy
Department of Biomedical Sciences and Human Oncology (DIMO), University of Bari "Aldo Moro", Italy
Department of Surgical Multidisciplinary, U.O.C. ‘General Surgery’, Ospedale Madonna Delle Grazie, Italy

^*Correspondance to: Chiara Maria Palmisano 

 PDF  Full Text Case Report | Open Access

Abstract:

Pyoderma Gangrenosum (PG) is a neutrophilic dermatosis characterized by skin infiltrations of polymorphonuclear leukocytes in the absence of vasculitis and infection [1]. Its main clinical features include the presence of inflammatory papules or pustules that usually progress to painful ulcers with a violaceous and undermined border. Commonly located on lower limbs, lesions typically seem as tender pustules or nodules that rapidly progress to ulcers with violaceous undermined borders [2]. Most cases occur in patients with an underlying systemic disorder, such as IBD in 0.4% to 2%, inflammatory arthritis, or hematological malignancies.

Keywords:

Pyoderma gangrenosum; Upadacitinib; Crohn’s disease

Cite the Article:

Palmisano CM, Novielli D, Pacello L, Cormio S, Borraccino V, Squeo F, et al. Upadacitinib in Concurrent Severe Pyoderma Gangrenosum and Crohn's Disease: Case Report and Literature Review. Clin Case Rep Int. 2024; 8: 1712..